RecruitingNot ApplicableNCT07234903

ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury

Sponsor

Ecole Polytechnique Fédérale de Lausanne

Enrollment

12 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

chronic spinal cord injury Spinal Cord Injury (SCI)Spinal Cord Injury SCI - Spinal Cord Injury SCI Subacute Spinal Cord Injury

Summary

The EIGER study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support and promote recovery of ambulatory functions, such as walking, in people with subacute and chronic spinal cord injury.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called ARC-IM Therapy for people with sci, sci - spinal cord injury, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEARC-IM Therapy

All participants will be treated with ARC-IM Therapy. The ARC-IM Lumbar System is intended to deliver electrical impulses to the lumbosacral region of the spinal cord to support ambulatory functions in people with SCI.